Over 50 Companies Advancing 55 Cannabinoid-Based Treatments Through Global Clinical Trials, Finds Report

The latest report from DelveInsight shows a surge of interest in cannabinoids such as THC, CBD, and emerging compounds like CBG and CBN, as evidence mounts for their therapeutic potential. Several key candidates are now in advanced stages of testing. Zynerba Pharmaceuticals’ ZYN-002, a transdermal cannabidiol gel without THC, is in Phase III trials for Fragile X syndrome. IGC Pharma is progressing IGC-AD1, a CB2 receptor agonist designed to treat Alzheimer’s by reducing neuroinflammation, currently in Phase II. Biopharmaceutical Research Company is developing BRC-002, an oral therapy granted FDA Orphan Drug Designation for Complex Regional Pain Syndrome, now in Phase I. Innocan Pharma’s Cannabidiol-loaded LPT, a liposomal CBD injection offering sustained release for up to six weeks, remains in preclinical testing but has shown strong results in chronic pain models.

The report also highlights promising mid- and early-stage developments, including therapies for obesity, agitation in Alzheimer’s patients, and cancer-related pain. Recent announcements include MIRA Pharmaceuticals’ preclinical data on Mira-55, a non-psychotropic marijuana analog providing morphine-comparable pain relief without causing inflammation, and InMed Pharmaceuticals’ findings that INM-901 can reduce neuroinflammation linked to Alzheimer’s disease.

Cannabinoid therapies under development span a range of formats, from synthetic and plant-derived small molecules to monoclonal antibodies and peptides, and are being tested across multiple delivery methods, including oral, transdermal, intravenous, and injectable forms.

In addition to THC and CBD, researchers are focusing on lesser-known cannabinoids with unique therapeutic profiles. CBG is being studied for glaucoma, CBN for insomnia, and synthetic cannabinoids like dronabinol and nabilone already have FDA approvals for nausea and appetite loss. Companies are also exploring cannabinoids for autoimmune disorders, PTSD, and opioid addiction, further expanding their potential medical applications.

With expanding clinical data, regulatory designations, and a diverse range of indications, the cannabinoid pipeline is poised for significant growth in the coming years. Many in the field believe that upcoming trial results could lead to new FDA approvals, adding to the limited but growing list of cannabinoid-based medicines currently on the market.

The uptick in cannabinoid research is likely to reach new levels if cannabis is rescheduled federally, with President Trump saying recently that a decision on the issue would come within “the next few weeks.”